(Q33347044)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

M E Gore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

H Thomas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

H Cure

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Rischin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

P Beale

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L Dirix

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

W M Smit

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R J Atkinson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

38 Suppl 8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

S7-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

Ovarian cancer: optimal chemotherapy in relapsed disease.

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Carboplatin: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980014-4

7 January 2021

10.1016/S0959-8049(02)80014-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12645907%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference